Prestige Consumer Healthcare (NYSE:PBH) Stock Gets Downgrade from Zacks Research

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Thursday, Zacks reports.

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $67.67.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH opened at $49.08 on Thursday. The stock has a fifty day moving average price of $48.54 and a two-hundred day moving average price of $54.20. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The firm has a market cap of $2.33 billion, a P/E ratio of 13.75, a PEG ratio of 1.53 and a beta of 0.34. Prestige Consumer Healthcare has a 1 year low of $42.62 and a 1 year high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.09. The company had revenue of $265.71 million during the quarter, compared to analyst estimates of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business’s revenue for the quarter was up 6.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Research analysts forecast that Prestige Consumer Healthcare will post 4.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter worth about $30,000. Versant Capital Management Inc increased its holdings in Prestige Consumer Healthcare by 47.9% in the second quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock worth $34,000 after buying an additional 235 shares during the last quarter. Cornerstone Planning Group LLC acquired a new position in Prestige Consumer Healthcare in the first quarter worth approximately $44,000. Pinnacle Wealth Planning Services Inc. raised its position in Prestige Consumer Healthcare by 69.3% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,153 shares of the company’s stock valued at $53,000 after acquiring an additional 472 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in Prestige Consumer Healthcare by 19.4% during the first quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the company’s stock valued at $91,000 after acquiring an additional 249 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.